Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma (pages 1202–1209)
Stephane Supiot, Alain Faivre-Chauvet, Olivier Couturier, Marie Françoise Heymann, Nelly Robillard, Françoise Kraeber-Bodéré, Laurence Morandeau, Marc Andrè Mahé and Michel Chérel
Article first published online: 12 FEB 2002 | DOI: 10.1002/cncr.10286
Using a specific monoclonal antibody, B-B4, coupled to bismuth-213 by a chelating agent (CITC-DTPA), the feasibility of alpha-radioimmunotherapy for multiple myeloma has been demonstrated previously. In this study, the two monoclonal antibodies tested, MA5 and B-B4, target the epithelial antigens Muc-1 and syndecan-1, respectively, which are both expressed by multiple myeloma cell lines. The results show that B-B4 might be the more effective therapeutic antibody and suggest that alpha-radioimmunotherapy might be more suitable than beta-radioimmunotherapy for treating single-cell tumor models.